Program
F8IL10
Its studies are mostly in Arthritis, Rheumatoid, led by Philogen.
Furthest: phase 2, since Oct 16, 20144 company-led studies, 1 open or runningNext primary completion: Sep 30, 2028 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Philogen | 41 open or running | phase 2since Oct 16, 2014 | Feb 24, 2014 | Sep 30, 2028phase 1 · NCT07245992 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 24, 2014First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT02076659 · 36 enrolled · Italy
- Oct 16, 2014Phase 2 study in Arthritis, RheumatoidNCT02270632 · 27 enrolled · Germany, Italy, Switzerland
- Nov 3, 2022Phase 1 study in Arthritis, RheumatoidNCT05622175
- Aug 19, 2025Phase 1 study in Arthritis, RheumatoidNCT07245992 · 54 planned · Italy
Ahead
- Sep 30, 2028Primary completion: phase 1 study in Arthritis, RheumatoidNCT07245992
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07245992Arthritis, Rheumatoid · Italy | 1 | Recruiting | Sep 30, 2028 | 54 |
| NCT05622175Arthritis, Rheumatoid | 1 | Withdrawn | Dec 31, 2025 | 0 |
| NCT02270632Arthritis, Rheumatoid · Germany, Italy, Switzerland | 2 | Terminated | Apr 2019 | 27 |
| NCT02076659Arthritis, Rheumatoid · Italy | 1 | Completed | Apr 2017 | 36 |
How it is read
Names in the registry
- “F8IL10”, 4 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.